

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): August 11, 2022**

---

**CTI BIOPHARMA CORP.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**000-28386**  
(Commission  
File Number)

**91-1533912**  
(I.R.S. Employer  
Identification Number)

**3101 Western Avenue, Suite 800**  
**Seattle, Washington 98121**  
(Address of principal executive offices)

**Registrant's telephone number, including area code: (206) 282-7100**

**Not applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, par value \$0.001</b>	<b>CTIC</b>	<b>Nasdaq Capital Market</b>

- Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
  - If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
- 
-

### Item 8.01. Other Events.

On August 11, 2022, BVF Partners L.P. (“BVF”), on behalf of itself and its affiliates (the “Reporting Persons”), filed a Schedule 13D/A with respect to its current ownership of shares of CTI BioPharma Corp. (the “Company”). As reported by BVF in its Schedule 13D/A filing, the Reporting Persons hold as of August 9, 2022 an aggregate (on an as-converted basis) of 45,283,021 shares of common stock of the Company, par value \$0.001 per share (the “Common Stock”) or 27.83% of the Company’s issued and outstanding shares of Common Stock (including, on an as-converted basis, all shares of the Company’s preferred stock).

The aggregate of 45,283,021 shares of Common Stock includes, as of August 9, 2022:

- 8,813,021 shares of Common Stock;
- 3,047 shares of Series X Preferred Stock, convertible into an aggregate of 30,470,000 shares of Common Stock; provided, however, the Series X Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion; and
- 600 shares of Series X1 Preferred Stock, convertible into an aggregate of 6,000,000 shares of Common Stock; provided, however, the Series X1 Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion.

The information in this Current Report on Form 8-K is furnished to, but not filed with, the Securities and Exchange Commission.

### Item 9.01. Financial Statements and Exhibits.

#### *(d) Exhibits*

Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:

<b>Exhibit No.</b>	<b>Description</b>	<b>Location</b>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CTI BIOPHARMA CORP.**

Date: August 15, 2022

By: \_\_\_\_\_ /s/ David H. Kirske  
David H. Kirske  
Chief Financial Officer